logo-loader

Adherium’s medication adherence device recognised by NICE

Published: 22:30 11 Jan 2017 GMT

shutterstock_396426208
Adherium’s medication adherence device recognised by NICE

The company’s shares were last trading at $0.260, up 8.3% intra-day.

Smartinhaler is Adherium’s proprietary digital platform which monitors inhaler use by patients with chronic respiratory disease, especially asthma.

The devices attach to prescription inhalers, providing reminders and analysis of inhaler usage, giving patients and healthcare professionals real-time data on medication use.

NICE is an independent organisation providing national guidance and advice to the UK’s National Health Service on medical treatments to improve healthcare.

The Medtech Innovation Briefing (MIB) published by NICE on Adherium’s Smartinhaler platform acknowledges its effectiveness compared to the current practices in asthma medication adherence.

MIBs provide clinicians with an up-to-date summary of innovative technologies, their uses and potential role in the treatment pathway.

The MIB summarised key points from five randomised controlled trials in the UK, Australia and New Zealand, involving a total of 589 people with asthma using Smartinhaler in a community setting.

Each trial showed that Smartinhaler devices were more effective than the current standard of care in improving adherence to asthma medication.

With Asthma costing the UK economy over £1.1 billion per year in medication costs and hospital admissions, there is a significant market for improving people’s quality of life through better asthma management.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

45 minutes ago